Hot Warren Buffett Stocks For 2021

Stocks discussed on the Lightning Round segment of Jim Cramer’s Mad Money Program, Monday, December 12.

Bullish Calls

Gilead (NASDAQ:GILD): Not likely to sell it, and could be a buy.

CyberArk (NASDAQ:CYBR): Bullish on stock.

Smith & Wesson (NASDAQ:SWHC): Stock appears cheap.

Bearish Calls

Ford (NYSE:F): Cramer said Ford is a good company, but GM (NYSE:GM) has better momentum. Also, Ford is in the crosshairs of incoming president Donald Trump.

PolyOne (NYSE:POL): Cramer likes the chemicals business, but his pick in the sector is Dow (NYSE:DOW).

Hot Warren Buffett Stocks For 2021: Bioanalytical Systems, Inc.(BASI)

Bioanalytical Systems, Inc., incorporated on July 17, 1975, is an international contract research organization providing drug discovery and development services and analytical instruments. The Company’s clients and partners include pharmaceutical, biotechnology, academic and government organizations. The Company derives its revenues from sales of its research services and drug development tools. The Company supports the preclinical and clinical development needs of researchers and clinicians for small molecule and biomolecule drug candidates. The Company’s principal clients are scientists engaged in analytical chemistry, drug safety evaluation, clinical trials, drug metabolism studies, pharmacokinetics and basic research from small start-up biotechnology companies to many of the global pharmaceutical companies. The Company operates in two business segments: contract research services and research products, both of which addresses the bioanalytical, preclinical, and clinical research needs of drug developers.

Services

This segment provides screening and pharmacological testing, preclinical safety testing, formulation development, regulatory compliance, and quality control testing. Product Characterization, Method Development, and Validation: Analytical methods, primarily performed in West Lafayette, Indiana, determine potency, purity, chemical composition, structure, and physical properties of a compound. Bioanalytical Testing: The Company analyzes specimens from preclinical and clinical trials to measure drug and metabolite concentrations in complex biological matrices. Bioanalysis is performed at its facilities in West Lafayette, Indiana. Stability Testing: The Company tests stability of drug substances and formulated drug products, and maintains storage facilities in West Lafayette, Indiana. In Vivo Pharmacology: The Company provides preclinical in vivo sampling services for the continuous monitoring of chemical changes in life, in particular, how a drug enters, travels thr! ough, and is metabolized in living systems. Those services are performed in customized facilities in West Lafayette and Evansville, Indiana using its robotic Culex Automated Pharmacology System. Preclinical and Pathology Services: The Company provides pharmacokinetic and safety testing in studies ranging from acute safety monitoring of drugs and medical devices to chronic, multi-year oncogenicity studies in its Evansville, Indiana site.

Research Products

This segment designs, develops, manufactures, and markets in vivo sampling systems and accessories (including disposables, training, and systems qualification); physiology monitoring tools; and liquid chromatography and electrochemistry instruments platforms. Analytical Products: The analytical products consist of the Company’s liquid chromatographic and electrochemical instruments with associated accessories. The critical component of these products is the Epsilon electrochemical platform. The market is principally academic institutions and industrial research companies. In vivo Sampling Products: The in vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments. These are used by pharmaceutical researchers to dose animals and collect biological samples (blood, bile, urine, microdialysate, feces or any bio-fluid) from the animals. The Culex products offer reduction in test model use and comparable reduction in labor. The line also includes in vivo sampling devices sold to drug developers and medical research centers to assist in the study of various medical conditions, including stroke, depression, Alzheimer’s and Parkinson’s diseases, diabetes, and osteoporosis. Vetronics’ Products: The Vetronics’ products consist of instruments and related software to monitor and diagnose cardiac function (electro-cardiogram), and measure other vital physiological parameters primarily in cats and dogs in veterinary clinics.

The Company competes with Covance, Inc.; Pharmaceut! ical Prod! uct Development, Inc.; Charles River Laboratories, Inc., and Quintiles Transnational Holdings, Inc.

Advisors’ Opinion:

  • [By Max Byerly]

    Headlines about Bioanalytical Systems (NASDAQ:BASI) have been trending positive this week, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioanalytical Systems earned a news sentiment score of 0.27 on Accern’s scale. Accern also gave media headlines about the company an impact score of 47.5882570492565 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Hot Warren Buffett Stocks For 2021: Heritage-Crystal Clean, Inc.(HCCI)

Heritage-Crystal Clean, Inc., through its subsidiary, Heritage-Crystal Clean, LLC, provides parts cleaning, and hazardous and non-hazardous waste services to small and mid-sized customers in the manufacturing and vehicle maintenance sectors. It operates in two segments: Environmental Services and Oil Business. The Environmental Services segment offers parts cleaning, containerized waste management, vacuum truck, and antifreeze recycling services. This segment also provides oily water disposal and treatment, oil filter recycling, on-site cleaning, and waste management services, as well as sells solvents, machines, absorbents, and accessories. The Oil Business segment collects used oil and sells recycled fuel oil, as well as engages in the re-refining of used oil into lubricant base oil and by-products. This segment also collects and disposes waste water. As of January 03, 2015, the company operated through 84 branches serving approximately 100,000 customer locations. Heritage-Crystal Clean, Inc. was incorporated in 2007 and is headquartered in Elgin, Illinois.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Heritage-Crystal Clean Inc  (NASDAQ:HCCI)Q4 2018 Earnings Conference CallMarch 06, 2019, 10:30 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    Shares of Heritage-Crystal Clean, Inc. (NASDAQ:HCCI) have received a consensus rating of “Buy” from the nine ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $25.40.

Hot Warren Buffett Stocks For 2021: Revlon, Inc.(REV)

Revlon, Inc., incorporated on April 24, 1992, manufactures, markets and sells around the world a range of beauty and personal care products, including color cosmetics, hair color, hair care and hair treatments, as well as beauty tools, men’s grooming products, anti-perspirant deodorants, fragrances, skincare and other beauty care products. The Company operates through three segments: Consumer, Professional and Other. The Company conducts its business through its operating subsidiary, Revlon Consumer Products Corporation (Products Corporation) and its subsidiaries.

The Company maintains separate Websites, including www.revlon.com, www.almay.com, www.revloncolorsilk.com, www.revlonprofessional.com, www.americancrew.com, www.cnd.com and www.mitchum.com, dedicated to the Revlon, Almay, Revlon ColorSilk, Revlon Professional, American Crew, CND and Mitchum brands, respectively. Each of these Websites feature product and promotional information for the brands. The Company operates a research and development facility in Edison, New Jersey for products within its Consumer segment. The Company has research facilities for its products within the Professional segment in the United States (in California and Florida), Spain and Mexico. The Company’s principal customers for its Consumer segment include large volume retailers and chain drug stores, including retailers, such as Walmart, CVS and Target in the United States, Shoppers DrugMart in Canada, A.S. Watson & Co. retail chains in Asia Pacific and Europe and Walgreens Boots Alliance in the United States and the United Kingdom Walmart and its affiliates around the world. The Company’s principal customers for its Professional segment include Beauty Systems Group, Salon Centric and Ulta Salon, Cosmetics and Fragrance, as well as individual hair and nail salons and other distributors to professional salons.

Consumer Segment

The Company’s Consumer segment includes cosmetics, hair color and hair care, beauty tools, anti-perspirant! deodorants, fragrances and skincare products sold in approximately 130 countries in large volume retailers, chain drug and food stores, chemist shops, hypermarkets, general merchandise stores, the Internet/e-commerce, television shopping, department stores, one-stop shopping beauty retailers, specialty cosmetics stores and perfumeries in the United States and internationally. The Company manufactures and markets a range of cosmetics, including face, lip, eye and nail products. The Company sells a range of cosmetics under its Revlon brand, which are designed to fulfill consumer wants and needs, and are principally priced in the upper range for large volume retailers. The Revlon brand consists of face makeup, including foundation, powder, blush and concealers; lip makeup, including lipstick, lip gloss and lip liner; eye makeup, including mascaras, eyeliners, eye shadows and brow products, and nail color and nail care lines. Its franchises within the Revlon brand include Revlon ColorStay, which offers consumers a range of products with long-wearing technology; Revlon PhotoReady products that are offered in face and eye makeup and are designed with photochromatic pigments that bend and reflect light; Revlon Age Defying, which consists of face makeup for women in the over-35 age bracket, with ingredients to help reduce the appearance of fine lines and wrinkles; Revlon Super Lustrous, which is the Company’s wax-based lipcolor and is offered in a range of shades of lipstick and lip gloss, and Revlon Mascara, which consists of a collection of over five mascaras, each with a lash benefit, including lash definition, length, volume, magnified volume and length, and an all-in-one formula.

The Company’s Almay brand consists of hypo-allergenic, dermatologist-tested, fragrance-free cosmetics and skincare products. The Almay brand consists of face makeup, including foundation, pressed powder, primer and concealer; eye makeup, including eye shadows, mascaras and eyeliners; lip makeup, and makeup removers. ! Franchise! s within the Almay brand include Almay Smart Shade in face; Almay Intense i-Color in eye, and Almay Color + Care in lip. The Company’s SinfulColors and Pure Ice brands consist primarily of nail enamels, available in various bold, vivid and on-trend colors.

The Company sells both hair color and hair care products throughout the world to large volume retailers and other retailers, primarily under the Company’s Revlon ColorSilk franchise, as well as under the premium priced Llongueras brand in Spain. Revlon ColorSilk products provide radiant, long-lasting color that leaves hair nourished, hydrated and ultra-conditioned. The Company sells Revlon beauty tools, which include nail, eye and manicure and pedicure grooming tools, eye lash curlers and a full line of makeup brushes under the Revlon brand name. The Company sells a selection of fragrances, including perfumes, eau de toilettes, colognes and body sprays. The Company’s portfolio includes fragrances under globally-recognized brand names, such as Charlie and Jean Nate. The Company sells Mitchum anti-perspirant deodorant products for men and women, with ingredients that provide consumers with approximately 48 hours of protection. The Company sells skincare products in the United States and in global markets under various regional brands, including the Company’s Natural Honey and Gatineau brands.

Professional Segment

The Company’s Professional segment includes a line of products sold to hair and nail salons, and professional salon distributors, including hair color, shampoos, conditioners, styling products, nail polishes and nail enhancements. The Professional segment also includes a multi-cultural line sold in both professional salons, large volume retailers and other retailers. The Company’s Revlon Professional brand includes hair color, hair care and hair treatment products that are distributed to professional salons, salon professionals and salon distributors, and sold in over 60 countries. Revlon Professional salo! n product! s include Revlonissimo NMT, Nutri Color Creme, Sensor Perm and Revlon Professional Equave.

The Company sells men’s shampoos, conditioners, gels and other hair care, and grooming products for use and sale by professional salons under the American Crew brand name. American Crew is sold in over 30 countries. The Company also sells unisex hair products under the d:fi brand, which is a value-priced full line of cleansing, conditioning and styling products. The Company sells nail enhancement systems and nail color and treatment products and services for use by the professional nail salon industry under the CND brand name. CND offers professional nail, hand and foot care products, and CND-branded products are sold in over 75 countries. CND nail products include CND Shellac brand 14+ day nail color system, which delivers 14+ days of flawless wear, superior color and mirror shine with zero dry-time and no nail damage, and CND Vinylux weekly polish, a nail polish that uses a patent-pending technology and lasts approximately a week. While ordinary polishes become brittle and deteriorate over time, CND Vinylux dries with exposure to natural light to a flawless finish and strengthens its resistance to chips over time. The Company also sells professional hair products under brand names, such as Orofluido, UniqOne and Intercosmo. The Company sells multi-cultural hair-care products to professional salons, large volume retailers and other retailers, primarily in the United States under the Creme of Nature brand.

Other Segment

The Company’s Other segment primarily includes the distribution of prestige, designer and celebrity fragrances, cosmetics and skincare products, such as Burberry and Rihanna branded products. The Other segment includes the operating results of the CBB business, which develops, manufactures, markets and distributes fragrances, and other beauty products, principally through department stores and selective distribution in international territories.

T! he Compan! y competes with L’Oreal S.A., The Procter & Gamble Company, Avon Products, Inc., Coty, Inc., Shiseido Co., Johnson & Johnson, Kao Corp., Henkel AG & Co., Mary Kay Inc., Hand & Nail Harmony, Inc., Oriflame Holding AG, Markwins International Corporation, LVMH Moet Henessy Louis Vuitton SE, Elizabeth Arden, Inc., Boots UK Limited and The Estee Lauder Companies Inc.

Advisors’ Opinion:

  • [By Max Byerly]

    Revlon (NYSE:REV) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a report issued on Tuesday.

  • [By Max Byerly]

    An issue of Revlon Inc (NYSE:REV) bonds fell 2% as a percentage of their face value during trading on Thursday. The high-yield debt issue has a 5.75% coupon and will mature on February 15, 2021. The debt is now trading at $80.50 and was trading at $84.88 one week ago. Price moves in a company’s bonds in credit markets often anticipate parallel moves in its share price.

  • [By Logan Wallace]

    News headlines about Revlon (NYSE:REV) have been trending somewhat positive recently, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Revlon earned a news sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the company an impact score of 47.276202232048 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Hot Warren Buffett Stocks For 2021: Kura Oncology, Inc.(KURA)

We are a clinical stage biopharmaceutical company discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. We focus on the development of small molecule product candidates that target cell signaling pathways that are important to driving the progression of certain cancers. We aim to employ molecular diagnostics to identify patients with cancers who are likely to benefit from our targeted product candidates.
Advancements in cancer genetics and new molecular diagnostic tools are helping define why some patients respond to a particular therapy while other patients receive little to no clinical benefit. This new era in cancer drug discovery and development offers the potential for innovative treatments that are safer and more effective for patients with particular cancers.   Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Kura Oncology, Inc.  (NASDAQ:KURA)Q4 2018 Earnings Conference CallMarch 05, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    BidaskClub lowered shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research note issued to investors on Tuesday morning.

  • [By Shane Hupp]

    Kura Oncology (NASDAQ:KURA) was the target of unusually large options trading on Thursday. Stock investors bought 699 put options on the company. This represents an increase of 694% compared to the typical daily volume of 88 put options.

Hot Warren Buffett Stocks For 2021: TRACON Pharmaceuticals, Inc.(TCON)

TRACON Pharmaceuticals, Inc., incorporated on October 28, 2004, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma.

TRC105

The Company is developing TRC105 for use in combination with agents that inhibit angiogenesis by targeting the VEGF pathway. VEGF is required for angiogenesis. TRC105 binds to the endoglin receptor at a precise location to inhibit endothelial cell activation and angiogenesis. TRC105 has been studied in over six completed Phase II clinical trials and approximately three completed Phase I clinical trials, and is being dosed in over five Phase II clinical trials. TRC105 is focused on approximately two orphan indications, gestational trophoblastic neoplasia (GTN) and angiosarcoma. The next tier of development includes ongoing Phase II trials in renal cell carcinoma, glioblastoma and hepatocellular carcinoma. The Company has produced formulations of TRC105 for development in ophthalmology, which are developed for the treatment of wet AMD, the cause of blindness in the Western world.

TRC205

The Company’s TRC205 is a humanized, deimmunized anti-endoglin antibody. TRC205 is being developed for the treatment of fibrotic diseases, including nonalcoholic ! steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).

TRC102

The Company is developing TRC102 (methoxyamine hydrochloride) to reverse resistance to specific chemotherapeutics by inhibiting base excision repair (BER). TRC102 interrupts BER by binding within apurinic/apyrimidinic (AP) sites, converting the AP site to a substrate for the enzyme topoisomerase II, which cleaves TRC102-bound deoxy ribonucleic acid (DNA), resulting in an accumulation of DNA strand breaks that trigger cellular apoptosis or programmed cell death. TRC102 is being developed to reverse resistance to Temodar, an alkylating chemotherapeutic, as well as to Alimta and Fludara, two antimetabolite chemotherapeutics. TRC102 began Phase II development through a Phase II clinical trial that combines TRC102 in patients with mesothelioma, as well as a Phase II clinical trial of TRC102 in patients with glioblastoma.

The Company competes with Pfizer, Inc., Acceleron Pharma Inc., Amgen, Inc., MedImmune LLC, OncoMed Pharmaceuticals Inc., Regeneron Pharmaceuticals, Inc., Roche AG, Genfit Corp., Intercept Pharmaceuticals, Inc., Conatus Pharmaceuticals Inc., Galmed Medical Research Ltd., Gilead Sciences, Inc., Immuron Ltd., Shire plc, Mochida Pharmaceutical Co., Ltd., NasVax Ltd., Raptor Pharmaceutical Corp., Takeda Pharmaceutical Company Limited, InterMune, Inc., Boehringer Ingelheim, Biogen Idec., Bristol-Myers Squibb, Celgene Corporation, Fibrogen, Inc., Gilead, Janssen Pharmaceuticals Inc., Novartis AG, Sanofi S.A, Tesaro, Inc. and AbbVie Inc.

Advisors’ Opinion:

  • [By Stephan Byrd]

    TRACON Pharmaceuticals Inc (NASDAQ:TCON) fell 12.3% during trading on Wednesday . The company traded as low as $1.23 and last traded at $1.21. 896,880 shares changed hands during trading, an increase of 112% from the average session volume of 422,831 shares. The stock had previously closed at $1.38.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on TRACON Pharmaceuticals (TCON)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Leave a Reply

Your email address will not be published. Required fields are marked *